Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

Authors: Brandon J. Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D. Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O. Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte

Source: Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)

Subject Terms: COVID-19, mRNA vaccine, booster, SARS-CoV-2 variants, safety, immunogenicity, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X

Access URL: https://doaj.org/article/b801d4c67eeb429f80a7051c7f35eae6